50.86
0.83 (1.66%)
| Previous Close | 50.03 |
| Open | 50.30 |
| Volume | 3,365,463 |
| Avg. Volume (3M) | 2,274,643 |
| Market Cap | 6,300,943,872 |
| Price / Sales | 7.73 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Guardant Health, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -5.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | -0.50 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.60% |
| % Held by Institutions | 97.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cadian Capital Management, Lp | 31 Mar 2025 | 4,595,087 |
| Eventide Asset Management, Llc | 31 Mar 2025 | 3,566,738 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (UBS, 37.63%) | Buy |
| Median | 60.00 (17.97%) | |
| Low | 57.00 (Scotiabank, 12.07%) | Buy |
| Average | 62.13 (22.16%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 47.45 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 13 Jun 2025 | 65.00 (27.80%) | Buy | 49.29 |
| 10 Apr 2025 | 55.00 (8.14%) | Buy | 41.14 | |
| Piper Sandler | 06 May 2025 | 60.00 (17.97%) | Buy | 41.93 |
| Scotiabank | 05 May 2025 | 57.00 (12.07%) | Buy | 44.05 |
| Barclays | 01 May 2025 | 60.00 (17.97%) | Buy | 48.87 |
| 10 Apr 2025 | 55.00 (8.14%) | Buy | 41.14 | |
| Canaccord Genuity | 01 May 2025 | 65.00 (27.80%) | Buy | 48.87 |
| Stifel | 01 May 2025 | 60.00 (17.97%) | Buy | 48.87 |
| TD Securities | 01 May 2025 | 60.00 (17.97%) | Buy | 48.87 |
| UBS | 01 May 2025 | 70.00 (37.63%) | Buy | 48.87 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CLARK IAN T | - | 49.53 | -6,672 | -330,464 |
| POTTER MYRTLE S | - | 49.94 | -2,652 | -130,777 |
| TARIQ MUSA | - | 50.57 | -3,213 | -162,481 |
| Aggregate Net Quantity | -12,537 | |||
| Aggregate Net Value ($) | -623,722 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 49.99 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| POTTER MYRTLE S | Director | 18 Jun 2025 | Sell (-) | 26 | 50.57 | 1,315 |
| TARIQ MUSA | Director | 18 Jun 2025 | Sell (-) | 3,213 | 50.57 | 162,481 |
| CLARK IAN T | Director | 17 Jun 2025 | Sell (-) | 6,672 | 49.53 | 330,464 |
| POTTER MYRTLE S | Director | 16 Jun 2025 | Sell (-) | 2,626 | 49.30 | 129,462 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |